The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-phthyl)ethyl]acetamide, on its own or in association, in obtaining medicaments intended for the treatment of bipolar disorders, especially bipolar disorders of types I and II, and more especially bipolar disorders of type I.